Telavancin in vitro activity against a collection of methicillin-resistant Staphylococcus aureus isolates, including resistant subsets, from the United States
about
Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience.Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.Telavancin (VIBATIV) for the treatment of complicated skin and skin structure infections.Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against Staphylococcus aureus.Efficacy of Telavancin Alone and in Combination with Ampicillin in a Rat Model of Enterococcus faecalis Endocarditis.Dosing strategies to optimize currently available anti-MRSA treatment options (Part 1: IV options).Update of the activity of telavancin against a global collection of Staphylococcus aureus causing bacteremia, including endocarditis (2011-2014)Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance.Pharmacokinetics of Telavancin at Fixed Doses in Normal Body Weight and Obese (Classes I, II, and III) Adult Subjects.Activity of Telavancin against Staphylococcus aureus Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients
P2860
Q34677611-725E7366-DF44-4566-8033-121B1B44C366Q35678198-24BC46F1-63AF-4E34-96A9-95FCA394C055Q38522574-09ACC56D-552C-400F-805B-D94A8B8E89DEQ38833633-608135FE-CED0-4B1C-843E-896A972E92C3Q38892614-AEAAC1B4-F89A-4777-88B3-1D897064D2BAQ38907793-4ACCD849-4B93-433F-9D12-A643C6F31CBAQ40362360-0B344BDB-2AD0-4514-8585-332EF3BF5AD5Q41028154-5D5482B6-1DAB-403D-AEF0-652D8A0214AFQ47172132-72CEA3BE-BED2-42F6-A8EE-E434B200F5BAQ58700574-12F157DB-B4D9-4E36-9ABE-49470724AB69
P2860
Telavancin in vitro activity against a collection of methicillin-resistant Staphylococcus aureus isolates, including resistant subsets, from the United States
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Telavancin in vitro activity a ...... ubsets, from the United States
@en
type
label
Telavancin in vitro activity a ...... ubsets, from the United States
@en
prefLabel
Telavancin in vitro activity a ...... ubsets, from the United States
@en
P2093
P2860
P356
P1476
Telavancin in vitro activity a ...... ubsets, from the United States
@en
P2093
David J Farrell
Rodrigo E Mendes
Ronald N Jones
P2860
P304
P356
10.1128/AAC.04616-14
P407
P577
2015-01-05T00:00:00Z